Kontakt
RSS
Impressum
Über uns
aktualisieren
Genentech’s Tecentriq in Combination With Abraxane Improves Outcomes as an Initial Treatment for People With PD-L1-Positive Metastatic Triple-Negative Breast Cancer. The Tecentriq and chemotherapy combination
clock-icon20.10.2018 - 16:53:46 Uhr | wallstreet-online.de

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive results from the Phase III IMpassion130 study of Tecentriq (atezolizumab) plus chemotherapy (Abraxane [albumin-bound paclitaxel; nab-paclitaxel]) for the initial (first-line) treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC)

Das könnte Sie auch interessieren:

GigCapital, Inc , (NYSE: GIG), a Private-to-Public Equity (PPE) corporation, formed for the purpose of entering into a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization or similar business combination with one or more businesses focused primarily on the Technology, Media and Telecommunications (TMT) markets, today announced that Executive Chairman of the


TherapeuticsMD, Inc (NASDAQ:TXMD), an innovative women’s healthcare company, today announced that the United States Food and Drug Administration (FDA) has approved BIJUVA (estradiol and progesterone) capsules, 1 mg/100 mg, the first and only FDA-approved bio-identical* hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate to severe


Pfizer Inc (NYSE:PFE) announced today that it has entered into a non-exclusive clinical development agreement with Novartis (NYSE: NVS) to investigate one or more combination therapies for the treatment of non-alcoholic steatohepatitis (NASH)


Regulatory News: NOXXON Pharma N V (Euronext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced today that it will report top-line efficacy data from the ongoing clinical trial (NCT03168139) testing NOX-A12 (olaptesed pegol) in combination with Merck & Co /MSD’s PD-1 inhibitor Keytruda in metastatic,


NEW YORK CITY - Bristol-Myers Squibb Co (BMY) today announced follow-up data evaluating Opdivo (nivolumab) monotherapy and Opdivo in combination with Yervoy (ipilimumab) in patients with platinum-pretreated metastatic urothelial carcinoma (mUC)